Creative Biolabs develops aptamer-functionalized nanocarriers for researchers who need selective delivery, improved cargo protection, controlled presentation, or target-dependent cellular uptake. Our support spans carrier selection, conjugation chemistry, formulation optimization, physicochemical characterization, and fit-for-purpose biological validation.
Discuss Your Aptamer-Nanocarrier ProjectWe provide custom development of aptamer-nanocarrier conjugates for targeted drug delivery, nucleic acid transport, imaging, biosensing, and mechanistic research. The program is designed for teams that have an aptamer and need a compatible carrier, have a nanocarrier and need a targeting ligand, or require an integrated system to be designed from the beginning.
Support can start with an existing sequence or be connected to our aptamer development service. When a targeting sequence has not yet been established, our one-stop aptamer in vitro selection service can be incorporated before carrier engineering. We translate target biology, cargo properties, route of administration, desired release behavior, and analytical endpoints into a practical conjugation and testing plan.
Carrier choice is treated as an engineering decision rather than a fixed starting point. We assess payload compatibility, surface chemistry, size target, stability requirements, release mechanism, biological environment, and the assays needed to demonstrate value. Researchers requiring a prepared targeting ligand can also explore our aptamer products.
Liposomes and related lipid systems can accommodate hydrophilic or hydrophobic cargo while providing a modifiable surface for aptamer display. Programs can evaluate composition, PEG spacing, ligand insertion, encapsulation, leakage, and release behavior.
Polymeric carriers support tunable size, degradation, and cargo release. We can develop aptamer-decorated particles or micellar systems and examine how polymer chemistry, terminal groups, and linker accessibility influence conjugation and function.
Gold, silica, magnetic, and other inorganic platforms offer distinct optical, magnetic, or surface properties. Development may use thiol coordination, silane chemistry, affinity handles, or orthogonal functional groups while controlling aggregation.
DNA assemblies, protein-linked carriers, and other biomolecular constructs enable programmable architectures. We help define aptamer placement, structural accessibility, cargo association, and nuclease or matrix stability.
Hybrid designs combine useful properties from multiple materials, such as lipid-coated inorganic particles or polymer-lipid systems. We assess whether added complexity creates measurable functional benefit and can be analytically controlled.
Existing nanocarriers can be functionalized or benchmarked when composition and surface handles are defined. Feasibility work identifies compatible chemistry, confirms particle tolerance, and sets acceptance criteria before scale-up.
We can begin with an interface compatibility review and a focused conjugation feasibility study.
A successful conjugate must preserve the aptamer fold, expose the binding region, retain colloidal stability, and present an appropriate number of ligands. We therefore optimize the interface as a system, not just confirm that covalent coupling occurred. Project-specific terminal groups and stability features can be supported through aptamer modification services, while pre-conjugation quality attributes can be examined through aptamer characterization services.
| Design Variable | Options We Can Evaluate | Development Question | Representative Readout |
|---|---|---|---|
| Aptamer format | DNA or RNA; terminally modified; spacer-equipped; stabilized sequence | Does modification preserve folding and target recognition? | Binding comparison before and after conjugation |
| Coupling route | Thiol-maleimide, amine-NHS, azide-alkyne, biotin-affinity, gold-thiol, or adsorption-based approaches | Is the reaction selective, reproducible, and compatible with the carrier? | Conjugation yield, free ligand, and particle integrity |
| Spacer architecture | PEG or alternative hydrophilic spacers with adjustable length | Is the aptamer sufficiently accessible above the carrier surface? | Target binding, serum behavior, and nonspecific association |
| Ligand density | Low-to-high surface loading or discrete input ratios | Where is the balance between avidity, stability, and steric crowding? | Ligand-per-particle estimate and functional dose response |
| Payload relationship | Encapsulated, adsorbed, complexed, intercalated, or co-conjugated cargo | Does aptamer installation alter loading, retention, or release? | Loading efficiency, leakage, release profile, and activity |
| Stimulus response | pH, reduction, enzymatic cleavage, light, or other project-defined triggers | Is cargo released in the intended biological compartment? | Condition-dependent release and functional response |
Controls may include unconjugated carrier, free aptamer, scrambled or nonbinding oligonucleotide, cargo-only carrier, target-negative cells, and competition conditions. These comparisons help distinguish true aptamer-mediated effects from surface charge, passive uptake, or formulation-driven changes.
If a payload rather than the carrier is the primary development variable, the program can connect with our ApDC development through therapeutic payload capabilities.
The sequence and depth of work are customized, but projects typically progress through five connected stages. Decision points can be built between stages so that additional optimization is triggered by data rather than assumption.
Align target, aptamer, cargo, carrier, biological model, comparator, success criteria, and intended downstream use.
Select surface chemistry, linker, purification route, analytical methods, and a focused experimental matrix.
Prepare initial formulations, install the aptamer, remove free components, and document process conditions.
Measure identity, size, distribution, charge, loading, aptamer density, stability, and release as applicable.
Compare binding, uptake, selectivity, delivery, and payload response using fit-for-purpose models and controls.
Combine sequence development, carrier conjugation, and biological validation under one coordinated study plan.
Assay selection is based on the carrier and the claim the data must support. A project may require a compact confirmation panel or a broader package that links physicochemical quality attributes to cellular performance.
Particle size, polydispersity, zeta potential, morphology, concentration, and aggregation assessment.
Free versus associated aptamer, coupling efficiency, ligand density estimate, and surface-accessibility studies.
Loading or encapsulation efficiency, retention, leakage, stimulus response, and release kinetics.
Short-term storage, freeze-thaw, dilution, serum or matrix challenge, and time-dependent particle behavior.
Biological validation can be designed around the proposed mechanism and available models:
Specific assays depend on target biology, carrier composition, payload, and model availability. Controls and acceptance criteria are agreed before study initiation. Broader functional studies can be coordinated with our aptamer in vitro analysis services or aptamer-based ELONA assay development.
We define the output package around the stage of your program. Early feasibility work emphasizes interpretable comparisons and a go/no-go recommendation; advanced studies can provide a more complete characterization and functional dataset for lead selection or downstream planning.
Each program includes scientific communication points so formulation or assay decisions can be reviewed before resources move to the next stage. Where appropriate, the final report distinguishes measured results from development recommendations and identifies remaining risks. Programs focused on complement targets may also connect with our broader complement component inhibitor development service.
Compare direct payload coupling with a nanocarrier format when architecture choice is still open.
These original studies illustrate how aptamer presentation, carrier architecture, cargo loading, and biological model selection can influence the evidence generated for a targeted nanocarrier.
Camorani and colleagues developed polymeric nanoparticles functionalized with a TNBC-targeting aptamer and evaluated selective uptake and siRNA-mediated PD-L1 silencing.
View research via DOI
Cadinoiu and colleagues investigated aptamer-functionalized liposomes carrying 5-fluorouracil, integrating formulation characterization with biological evaluation in basal cell carcinoma models.
View research via DOI
Seo and colleagues built AS1411-conjugated, doxorubicin-loaded DNA-protein nanospheres and examined active targeting in cellular, 3D spheroid, and in vivo glioblastoma models.
View research via DOIYes. We can review an existing DNA or RNA aptamer, its available terminal modifications, target-binding evidence, and compatibility with the proposed carrier. If further sequence discovery or optimization is needed, the nanocarrier program can be coordinated with our aptamer development capabilities.
Programs may involve liposomes, polymeric nanoparticles or micelles, gold or other inorganic nanoparticles, magnetic particles, DNA or biomolecular nanostructures, hybrid carriers, and customer-supplied formulations. Final selection depends on cargo, surface chemistry, size requirements, stability, release behavior, and intended biological use.
Potential strategies include thiol-maleimide, amine-NHS, azide-alkyne, biotin-affinity, gold-thiol, and other carrier-compatible chemistries. The best route is selected after reviewing the carrier surface, aptamer modification, desired orientation, linker needs, and tolerance of both components to the reaction conditions.
Yes. Ligand density can be evaluated across selected input ratios and correlated with conjugation yield, particle stability, target binding, uptake, and nonspecific association. This helps identify a practical density range rather than assuming that maximum loading produces the best function.
Depending on the carrier, projects may involve small molecules, oligonucleotides such as siRNA, proteins or peptides, fluorescent probes, imaging agents, or other research payloads. A feasibility review is used to confirm loading route, analytical detection, retention, release, and compatibility.
We combine physicochemical evidence of conjugation with an appropriate binding comparison. Studies may compare free and conjugated aptamer, evaluate target-positive and target-negative models, use competition or blocking conditions, and measure target-dependent uptake or payload delivery.
Helpful starting information includes the target and application, aptamer sequence and modifications, available binding data, carrier composition and surface handles, payload properties, desired formulation attributes, biological model, required controls, material quantities, and the decision the final data should support.
Complement Activity/Function Assay Products
Learn More
Complement Testing Services
Learn More
Complement Therapeutics Featured Products
Learn More
Complement Therapeutics Services Brochure
Learn More
Aptamer Development PLATFORM
Learn More
ComPLETTM Hemolysis Assay Solutions
Learn More